Antiviral drug therapy- exploiting medicinal plants

Journal of Antivirals and Antiretrovirals

Volumn 5, Issue 2, 2013, Pages

  Babar, Mustafeez ^a   Najam us Sahar, Sadaf Zaidi ^a   Ashraf, Muhammad ^a   Kazi, Alvina Gul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT;

ANTIVIRAL THERAPY; DENGUE VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MEDICINAL PLANT; REVIEW; VIRUS ATTACHMENT;

DENGUE VIRUS; ORTHOMYXOVIRIDAE;

EID: 84876929870     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000060     Document Type: Review

References (136)

1. World Health Organization (1996) The World Health Report 1996: Fighting disease, fostering development. World Health Organization, Geneva.
2. World Health Organization (2002) Scaling up the response to infectious diseases: a way out of poverty: report on infectious diseases 2002. World Health Organization, Geneva.
3. Bokazhanova A, Rutherford GW (2006) The epidemiology of HIV and AIDS in the world. Coll Antropol 30: 3-10.
4. Elderfield R, Barclay W (2012) Influenza pandemics. Adv Exp Med Biol 719: 81-103.
5. WHO (2010) WHO's role and responsibilities in health research: Draft WHO strategy on research for health: Report by the Secretariat. World Health Organization, Geneva.
6. Evans AS, Kaslow RA (1997) Viral infections of humans: Epidemiology and Control. (4thedn.), Springer.
7. Goodbourn S, Didcock L, Randall RE (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81: 2341-2364.
8. Nathanson N, Tyler KL (2010) Pathogenesis of viral infections. Topley and Wilson's Microbiology and Microbial Infections.
9. Mercer J, Schelhaas M, Helenius A (2010) Virus entry by endocytosis. Annu Rev Biochem 79: 803-833.
10. Khadka S, Vangeloff AD, Zhang C, Siddavatam P, Heaton NS, et al. (2011) A physical interaction network of dengue virus and human proteins. Mol Cell Proteomics 10.
11. Feschotte C, Gilbert C (2012) Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet 13: 283-296.
12. Desfarges S, Ciuffi A (2012) Viral Integration and Consequences on Host Gene Expression. 147-175.
13. Swanstrom R, Wills JW (1997) Synthesis, Assembly, and Processing of Viral Proteins. In: Coffin JM, Hughes SH and Varmus HE, Retroviruses, Cold Spring Harbor, NY.
14. Nayak DP, Hui EK, Barman S (2004) Assembly and budding of influenza virus. Virus Res 106: 147-165.
15. Agol VI (2012) Cytopathic effects: virus-modulated manifestations of innate immunity? Trends Microbiol 20: 570-576.
16. Mothes W, Sherer NM, Jin J, Zhong P (2010) Virus Cell-to-Cell Transmission. J Virol 84: 8360-8368.
17. Ena J, Pasquau F (2003) Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 36: 1186-1190.
18. Lüscher-Mattli M (2000) Influenza chemotherapy: a review of the present state of art and of new drugs in development. Arch Virol 145: 2233-2248.
19. Roberts NA (2001) Anti-influenza drugs and neuraminidase inhibitors. Prog Drug Res 35-77.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB (2008) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
21. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
22. Poland GA, Jacobson RM, Ovsyannikova IG (2009) Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 48: 1254-1256.
23. Choi KT (2008) Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacol Sin 29: 1109-1118.
24. Park HJ, Kurokawa M, Shiraki K, Nakamura N, Choi JS, et al. (2005) Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice. Biol Pharm Bull 28: 2258-2262.
25. Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, et al. (1995) Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med 1: 361-369.
26. Joseph B, Raj SJ (2011) An overview: Pharmacognostic properties of Phyllanthus amarus Linn. Int J Pharmacol 7: 40-45.
27. Kinghorn ADE, Balandrin MF (1993) Human medicinal agents from plants: Symposium. American Chemical Society, Washington, DC.
28. Serkedjieva J, Nikolova E, Kirilov N (2010) Synergistic inhibition of influenza A virus replication by a plant polyphenol-rich extract and epsilon-aminocaproic acid in vitro and in vivo. Acta Virol 54: 137-145.
29. Amoros M, Simõs C, Girre L, Sauvager F, Cormier M (1992) Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis. J Nat Prod 55: 1732-1740.
30. Clercq ED (2012) Highlights in Antiviral Drug Research: Antivirals at the Horizon. Med Res Rev.
31. Chiang LC, Ng LT, Cheng PW, Chiang W, Lin CC (2005) Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin Exp Pharmacol Physiol 32: 811-816.
32. Shin WJ, Lee KH, Park MH, Seong BL (2009) Broad-spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses. Microbiol Immunol 54: 11-19.
33. Alen MM, De Burghgraeve T, Kaptein SJ, Balzarini J, Neyts J, et al. (2011) Broad Antiviral activity of Carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PloS One 6: e21658.
34. Wu Q, Yu C, Yan Y, Chen J, Zhang C, et al. (2010) Antiviral flavonoids from Mosla scabra. Fitoterapia 81: 429-433.
35. Flexner C (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6: 959-966.
36. Hupfeld J, Efferth T (2009) Drug resistance of human immunodeficiency virus and overcoming it by natural products. In Vivo 23: 1-6.
37. Loya S, Rudi A, Kashman Y, Hizi A (1999) Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases. Biochem J 344: 85-92.
38. Belardelli F (2009) Role of interferons and other cytokines in the regulation of the immune response. APMIS 103: 161-179.
39. Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
40. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-1309.
41. Jones TC (2009) Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF). Stem Cells 12: 229-240.
42. Hultgren C, Milich DR, Weiland O, Sällberg M (1998) The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 79: 2381-2391.
43. Brüll F, Mensink RP, Plat J (2009) Plant sterols: functional lipids in immune function and inflammation? Clin Lipidol 4: 355-365.
44. Yang J (2009) Brazil nuts and associated health benefits: A review. LWT-Food Science and Technology 42: 1573-1580.
45. Patwardhan B, Gautam M (2005) Botanical immunodrugs: scope and opportunities. Drug Discov Today 10: 495-502.
46. Nair PK, Rodriguez S, Ramachandran R, Alamo A, Melnick SJ, et al. (2004) Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia. Int Immunopharmacol 4: 1645-1659.
47. Mishima S, Saito K, Maruyama H, Inoue M, Yamashita T, et al. (2004) Antioxidant and immuno-enhancing effects of Echinacea purpurea. Biol Pharm Bull 27: 1004-1009.
48. Aridogan BC (2006) Immunomodulatory Effects of Phytocompounds. Chapter 16, Modern Phytomedicine: Turning Medicinal Plants into Drugs. Wiley-VCH, Weinheim.
49. Butt MS, Sultan MT, Butt MS, Iqbal J (2009) Garlic: nature's protection against physiological threats. Crit Rev Food Sci Nutr 49: 538-551.
50. Bozek K, Lengauer T, Domingues F (2011) Physicochemical and structural properties determining HIV-1 coreceptor usage. Moscow Conference on Computational Molecular Biology 74-75.
51. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, et al. (2008) CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 82: 5007-5020.
52. Harrison SC (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690-698.
53. Müller B, Kräusslich HG (2009) Antiviral strategies. Handb Exp Pharmacol 1-24.
54. Rosenthal KS, Sokol MS, Ingram RL, Subramanian R, Fort RC (1982) Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother 22: 1031-1036.
55. Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, et al. (1998) CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol 161: 3103-3113.
56. Lieberman-Blum SS, Fung HB, Bandres JC (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30: 1228-1250.
57. Klibanov OM (2009) Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 10: 845-859.
58. Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, et al. (1998) The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res 40: 85-94.
59. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185.
60. Ang SP (2011) Compositions For Treating Chronic Viral Infections. Google Patents.
61. Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, et al. (2004) Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 48: 3858-3870.
62. Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, et al. (2007) Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 75: 179-187.
63. Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, et al. (2008) Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem 51: 2638-2647.
64. Yao WH, Zhao W, Wu YW, Zhao H, Wei HX, et al. (2006) [Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS patients]. Zhonghua Nan Ke Xue 12: 598-601.
65. Il'ina TV, Fediuk NV, Bachinskii AG, Tumanova O, Kuvshinov VN, et al. (2003) [Determination of glycyrrhizic acid binding sites by a phage display method]. Mol Biol (Mosk) 37: 861-867.
66. Notka F, Meier G, Wagner R (2003) Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res 58: 175-186.
67. An T, Ouyang W, Pan W, Guo D, Li J, et al. (2012) Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1. Antiviral Res 94: 276-287.
68. Chang YS, Woo ER (2003) Korean medicinal plants inhibiting to Human Immunode?ciency Virus type 1 (HIV-1) fusion. Phytother Res 17: 426-429.
69. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
70. Talarico LB, Damonte EB (2007) Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363: 473-485.
71. Nagata K, Kawaguchi A, Naito T (2008) Host factors for replication and transcription of the influenza virus genome. Rev Med Virol 18: 247-260.
72. Malys N, McCarthy JE (2011) Translation initiation: variations in the mechanism can be anticipated. Cell Mol Life Sci 68: 991-1003.
73. Klibanov OM (2009) Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 10: 190-200.
74. Hicks C, Gulick RM (2009) Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 48: 931-939.
75. LaFemina RL (2009) Antiviral Research: strategies in antiviral drug discovery. American Society for Microbiology.
76. Narayanan A, Bailey C, Kashanchi F, Kehn-Hall K (2011) Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses. Expert Opin Investig Drugs 20: 239-254.
77. Upadhyay RK (2011) Plant latex: A natural source of pharmaceuticals and pesticides. IJGP 5: 169-180.
78. Buckheit RW Jr, White EL, Fliakas-Boltz V, Russell J, Stup TL, et al. (1999) Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 43: 1827-1834.
79. Chen K, Shi Q, Fujioka T, Zhang DC, Hu CQ, et al. (1992) Anti-AIDS agents, 4. Tripterifordin, a novel anti-HIV principle from Tripterygium wilfordii: isolation and structural elucidation. J Nat Prod 55: 88-92.
80. Spino C, Dodier M, Sotheeswaran S (1998) Anti-HIV coumarins from Calophyllum seed oil. Bioorg Med Chem Lett 8: 3475-3478.
81. Zhou P, Takaishi Y, Duan H, Chen B, Honda G, et al. (2000) Coumarins and bicoumarin from Ferula sumbul: anti-HIV activity and inhibition of cytokine release. Phytochemistry 53: 689-697.
82. Shu S, Xie G, Guo X, Wang M (2009) Purification and characterization of a novel ribosome-inactivating protein from seeds of Trichosanthes kirilowii Maxim. Protein Expr Purif 67: 120-125.
83. Chen KX, Njoroge FG (2009) A review of HCV protease inhibitors. Curr Opin Investig Drugs 10: 821-837.
84. De Clercq E (2008) Antivirals: current state of the art. Future Virol 3: 393-405.
85. Lew W, Wang MZ, Chen X, Rooney JF, Kim C (2011) Neuraminidase Inhibitors as Anti-Influenza Agents. Antiviral Drug Strategies 351-376.
86. Kim JY, Park SC, Hwang I, Cheong H, Nah JW, et al. (2009) Protease inhibitors from plants with antimicrobial activity. Int J Mol Sci 10: 2860-2872.
87. Maridass M, Raju G, Thangavel K, Ghanthikumar S (2008) Prediction of Anti-Hiv Activity of Flavanoid Constituents Through PASS. Ethnobotanical Leaflets 12: 954-994.
88. Chudiwal A, Jain D, Somani R (2010) Alpinia galanga Willd.-An overview on phyto-pharmacological properties. IJNPR 1: 143-149.
89. Singh C, Nongalleima K, Brojendrosingh S, Ningombam S, Lokendrajit N, et al. (2012) Biological and chemical properties of Zingiber zerumbet Smith: a review. Phytochem Rev 11: 113-125.
90. Tewtrakul S, Subhadhirasakul S, Kummee S (2003) HIV-1 protease inhibitory effects of medicinal plants used as self medication by AIDS patients. Songklanakarin Journal of Science and Technology 25: 239-243.
91. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, et al. (2007) Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3', 3'-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 51: 3574-3581.
92. Hsieh CF, Yen HR, Liu CH, Lin S, Horng JT (2012) Ching-fang-pai-tu-san inhibits the release of influenza virus. J Ethnopharmacol 144: 533-544.
93. Kadam N, Chaudhari H, Parikh J, Modi V, Kokil S, et al. (2010) De novo combination therapy in retroviral infection. Int J Virol 6: 219-223.
94. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, et al. (2009) Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. Hepatol Res 39: 60-69.
95. Graci JD, Cameron CE (2008) Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol 3: 553-566.
96. Chen YP, Chen F (2008) Identifying targets for drug discovery using bioinformatics. Expert Opin Ther Targets 12: 383-389.
97. Jorgensen WL (2009) Efficient drug lead discovery and optimization. Acc Chem Res 42: 724-733.
98. Ivanova E, Toshkova R, Serkedjieva J (2005) A plant polyphenol-rich extract restores the suppressed functions of phagocytes in influenza virus-infected mice. Microbes Infect 7: 391-398.
99. Fraile L, Crisci E, Córdoba L, Navarro MA, Osada J, et al. (2012) Immunomodulatory properties of Beta-sitosterol in pig immune responses. Int Immunopharmacol 13: 316-321.
100. Mishra G, Singh P, Verma R, Kumar S, Srivastav S, et al. (2011) Traditional uses, phytochemistry and pharmacological properties of Moringaoleifera plant: An overview. Der Phamacia Lettre 3: 141-164.
101. Hudson J, Vimalanathan S (2011) Echinacea-A source of potent antivirals for respiratory virus infections. Pharmaceuticals 4: 1019-1031.
102. Ulbricht C (2012) Herpes: An Integrative Approach-A Natural Standard Monograph. Alternative and Complementary Therapies 18: 269-276.
103. Ji X, Gewurz H, Spear GT (2005) Mannose binding lectin (MBL) and HIV. Mol Immunol 42: 145-152.
104. Anders EM, Hartley CA, Jackson DC (1990) Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins. Proc Natl Acad Sci U S A 87: 4485-4489.
105. Balzarini J, Schols D, Neyts J, Van Damme E, Peumans W, et al. (1991) Alpha-(1-3)-and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother 35: 410-416.
106. Regan AD, Ousterout DG, Whittaker GR (2010) Feline lectin activity is critical for the cellular entry of feline infectious peritonitis virus. J Virol 84: 7917-7921.
107. Moatari A, Nekooeian AA, Motamedifard M (2006) The Antiinfluenza Virus Activity of Hydroalcoholic Extract of Olive Leaves. Iranian Journal of Pharmaceutical Sciences 2: 163-168.
108. Motamedifar M, Nekooeian AA, Moatari A (2007) The effect of hydroalcoholic extract of olive leaves against herpes simplex virus type 1. IJMS 32: 222-226.
109. Thompson KD, Dragar C (2004) Antiviral activity of Undariapinnati?da against herpes simplex virus. Phytother Res 18: 551-555.
110. Takahashi K, Matsuda M, Ohashi K, Taniguchi K, Nakagomi O, et al. (2001) Analysis of anti-rotavirus activity of extract from Stevia rebaudiana. Antiviral Res 49: 15-24.
111. Ito M, Nakashima H, Baba M, Pauwels R, De Clercq E, et al. (1987) Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antiviral Res 7: 127-137.
112. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, et al. (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361: 2045-2046.
113. Crance J-M, Lévêque F, Biziagos E, van Cuyck-Gandré H, Jouan A, et al. (1994) Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res 23: 63-76.
114. Aron GM, Irvin JD (1980) Inhibition of herpes simplex virus multiplication by the pokeweed antiviral protein. Antimicrob Agents Chemother 17: 1032-1033.
115. Erice A, Balfour HH Jr, Myers DE, Leske VL, Sannerud KJ, et al. (1993) Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob Agents Chemother 37: 835-838.
116. He YW, Guo CX, Pan YF, Peng C, Weng ZH (2008) Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro. World J Gastroenterol 14:1592-1597.
117. Nichols JE, Niles JA, Roberts NJ Jr (2001) Human lymphocyte apoptosis after exposure to influenza A virus. J Virol 75: 5921-5929.
118. Yin Low JS, Chen KC, Wu KX, Mah-Lee NM, Hann Chu JJ (2009) Antiviral activity of emetine dihydrochloride against dengue virus infection. J Antivir Antiretrovir 1: 062-071.
119. Handa H, Sharp PA (1980) Expression of early and late simian virus 40 transcripts in the absence of protein synthesis. J Virol 34: 592-597.
120. Choi HJ, Song JH, Park KS, Kwon DH (2009) Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. Eur J Pharm Sci 37: 329-333.
121. Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, et al. (2009) The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. Hepatology 50: 1756-1764.
122. Johari J, Kianmehr A, Mustafa MR, Abubakar S, Zandi K (2012) Antiviral Activity of Baicalein and Quercetin against the Japanese Encephalitis Virus. Int J Mol Sci 13: 16785-16795.
123. Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, et al. (2011) In vitro antiviral activity of Fisetin, Rutin and Naringenin against Dengue virus type-2. Journal of Medicinal Plants Research 5: 5534-5539.
124. Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, et al. (2012) Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Methods 182: 93-98.
125. Saha RK, Takahashi T, Suzuki T (2009) Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase. Biol Pharm Bull 32: 1188-1192.
126. Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, et al. (2011) Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol 55: 963-971.
127. Lomenick B, Olsen RW, Huang J (2010) Identification of direct protein targets of small molecules. ACS Chem Biol 6: 34-46.
128. Too PH, Ma MK, Mak AN, Wong YT, Tung CK, et al. (2009) The C-terminal fragment of the ribosomal P protein complexed to trichosanthin reveals the interaction between the ribosome-inactivating protein and the ribosome. Nucleic Acids Res 37: 602-610.
129. Rankovic Z, Morphy R (2010) Fragment-Based Lead Discovery. In: Albert JS Lead Generation Approaches in Drug Discovery. 105-139.
130. Pflug A (2012) Protein kinase selectivity mechanisms and structure assisted drug discovery. Doctoral thesis, University of Tromsø.
131. Jhoti H (2008) Fragment-based drug discovery using rational design. Sparking Signals Ernst Schering Foundation Symposium Proceedings 3: 169-185.
132. Rautio J (2011) Prodrug strategies in drug design. Prodrugs and Targeted Delivery: Towards Better ADME Properties.
133. Atkins C, Evans CW, White EL, Noah JW (2012) Screening methods for influenza antiviral drug discovery. Expert Opin Drug Discov 7: 429-438.
134. Puig-Basagoiti F, Deas TS, Ren P, Tilgner M, Ferguson DM, et al. (2005) High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother 49: 4980-4988.
135. Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, et al. (1978) Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1: 463-466.
136. Ambrose Z, KewalRamani VN, Bieniasz PD and Hatziioannou T (2007) HIV/AIDS: in search of an animal model. Trends Biotechnol 25: 333-337.